Human skin replacement - Amarantus Bioscience

Drug Profile

Human skin replacement - Amarantus Bioscience

Alternative Names: Cultured skin substitute - Amarantus Bioscience; Engineered skin substitute - Amarantus Bioscience; ESS-W; PermaDerm

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lonza
  • Developer Amarantus Bioscience Holdings
  • Class Cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Burns
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Burns
  • Clinical Phase Unknown Nevus

Most Recent Events

  • 01 Dec 2017 Human skin replacement is still undergoing clinical development for Nevus in USA
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Nevus(In children, In infants) in USA (Topical)
  • 13 Sep 2016 Phase-II clinical trials in Burns in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top